Blood Cancer Treatment in India
Get Blood Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Blood Cancer Treatment in UAE
Blood Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Blood cancer — encompassing leukemia, lymphoma, and multiple myeloma — requires highly specialized, protocol-driven oncology care that combines chemotherapy, targeted biologics, immunotherapy, and, when indicated, hematopoietic stem cell transplantation (HSCT). Leading cancer centers in India and the UAE report five-year survival rates ranging from 60% to over 85% for many blood cancer subtypes when diagnosed and treated at an advanced, high-volume institution. GAF Healthcare connects international patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, providing end-to-end oncology coordination at a fraction of Western treatment costs.
Hospital Stay: 14–42 days (varies by protocol: induction chemotherapy, transplant conditioning, or CAR-T cell infusion cycles) • Total Stay in Country (Fit-to-Fly): 6–16 weeks (depending on treatment modality; stem cell transplant patients require a minimum of 90 days in-country post-engraftment before international travel is medically cleared) • Success Rate: 60–88% (5-year overall survival; subtype- and stage-dependent — ALL in children: ~88%; DLBCL with R-CHOP: ~65–70%; AML complete remission after induction: ~60–80%; Multiple Myeloma progression-free survival at 5 years with novel agents: ~50–60%)
What Is It?
Blood cancers arise from the uncontrolled proliferation of malignant hematopoietic cells within the bone marrow, lymphatic system, or peripheral blood. The three principal categories — leukemia (acute and chronic), lymphoma (Hodgkin and Non-Hodgkin), and multiple myeloma (a plasma cell dyscrasia) — each disrupt normal blood cell production in distinct ways. In leukemia, blasts crowd the marrow, impairing erythropoiesis and thrombopoiesis, leading to anemia, hemorrhagic risk, and severe immunosuppression. Lymphomas originate in lymphoid tissue and can be nodal or extranodal, with Non-Hodgkin lymphoma (NHL) representing over 30 distinct WHO-classified subtypes. Multiple myeloma causes osteolytic bone lesions, hypercalcemia, renal impairment, and recurrent infections via monoclonal immunoglobulin deposition.
The physiological burden of blood cancer extends beyond the primary malignancy. Cytopenia-related complications — including febrile neutropenia, transfusion dependency, and coagulopathy — demand continuous inpatient monitoring and supportive care. Central nervous system involvement (CNS sanctuary disease in ALL), mediastinal compression in T-cell lymphoma, and renal failure secondary to light-chain deposition in myeloma require multidisciplinary management across hematology, nephrology, neurology, and infectious disease specialists.
The global standard of care is defined by risk-stratified, protocol-based therapy. Molecular profiling — including cytogenetic karyotyping, FISH for chromosomal translocations (e.g., BCR-ABL1 in CML, t(15;17) in APL, t(14;18) in follicular lymphoma), next-generation sequencing (NGS) panels, and flow cytometric immunophenotyping — drives treatment selection. Frontline regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for aggressive B-cell NHL, HyperCVAD for ALL, and VRd (bortezomib, lenalidomide, dexamethasone) for multiple myeloma have been complemented by second- and third-generation targeted agents and cellular therapies, including CAR-T cell therapy and bispecific antibodies, now available at select centers in both India and the UAE.
Candidates
• ELIGIBILITY — DIAGNOSIS-CONFIRMED CASES: Patients with histopathologically confirmed blood cancer (bone marrow biopsy, lymph node biopsy, or trephine biopsy) who require induction chemotherapy, consolidation, maintenance therapy, or hematopoietic stem cell transplantation (autologous or allogeneic HSCT).
• NEWLY DIAGNOSED PATIENTS: Those in need of frontline protocol initiation — including pediatric and adult ALL, AML, CML in chronic/accelerated phase, Hodgkin lymphoma, aggressive and indolent NHL, and newly diagnosed multiple myeloma.
• RELAPSED OR REFRACTORY DISEASE: Patients who have failed one or more prior lines of therapy and require salvage regimens (e.g., R-ICE, R-DHAP, ESHAP for lymphoma; azacitidine or venetoclax-based combinations for AML) or access to CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel) or bispecific T-cell engager therapy.
• STEM CELL TRANSPLANT CANDIDATES: Patients with AML, ALL, CML, MDS, or chemosensitive relapsed lymphoma eligible for myeloablative or reduced-intensity conditioning (RIC) allogeneic HSCT, or autologous HSCT for myeloma and relapsed Hodgkin/NHL.
• REQUIRED DIAGNOSTICS BEFORE TRAVEL: Complete blood count (CBC) with differential and peripheral blood smear; bone marrow aspirate and trephine biopsy with immunohistochemistry (IHC); flow cytometry for immunophenotyping (CD markers panel); cytogenetics — conventional karyotype and FISH; molecular studies — BCR-ABL1 PCR (CML/ALL), FLT3/IDH1/IDH2/NPM1/CEBPA mutation panel (AML), JAK2/CALR/MPL (MPN); NGS panel (hematologic malignancies); serum protein electrophoresis (SPEP), immunofixation, free light chain assay (for myeloma); CT-PET scan (whole body, for lymphoma staging); MRI spine/brain (if CNS involvement suspected); ECHO/echocardiography (pre-anthracycline therapy cardiotoxicity baseline); HLA typing (for allogeneic HSCT candidates and potential sibling donors); Liver function tests, renal function panel, viral serology (HIV, HBV, HCV, CMV, EBV — mandatory pre-transplant).
• CONTRAINDICATIONS / RELATIVE EXCLUSIONS: ECOG performance status ≥3 with rapidly deteriorating organ function unless treatment intent is palliative; uncontrolled active systemic infection at the time of planned travel; severe cardiac dysfunction (LVEF <35%) precluding anthracycline-based regimens without cardiology clearance; end-stage renal failure not manageable with dose-adjusted protocols; patients who are critically unstable and require ICU-level care before any planned transfer.
Procedure
CHEMOTHERAPY PROTOCOLS (STANDARD OF CARE)
Induction, consolidation, and maintenance chemotherapy remain the backbone of blood cancer treatment. Regimens are protocol-driven and disease-specific:
• Acute Myeloid Leukemia (AML): Standard '7+3' induction (cytarabine continuous infusion × 7 days + daunorubicin × 3 days); for FLT3-mutated AML, midostaurin is added (RATIFY protocol); IDH1/IDH2-mutated AML is treated with ivosidenib or enasidenib as targeted agents in frontline or relapsed settings. Gemtuzumab ozogamicin (GO) is incorporated in CD33-positive favorable-risk AML.
• Acute Lymphoblastic Leukemia (ALL): HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate/cytarabine; for Philadelphia chromosome-positive ALL (BCR-ABL1+), a second-generation TKI (dasatinib or ponatinib) is mandatory. Blinatumomab (CD19/CD3 bispecific) and inotuzumab ozogamicin (CD22-targeted) are used in MRD-positive or relapsed/refractory ALL, supported by CNS prophylaxis via intrathecal methotrexate/cytarabine.
• Chronic Myeloid Leukemia (CML): First-line tyrosine kinase inhibitor (TKI) therapy — imatinib (generic, affordable), dasatinib, nilotinib, or bosutinib (second-generation); ponatinib or asciminib for T315I-mutant or TKI-resistant disease. Deep molecular response (DMR) monitoring by BCR-ABL1 PCR (IS) is performed at 3, 6, and 12 months to guide TKI continuation, switch, or potential treatment-free remission (TFR) attempt.
• Hodgkin Lymphoma: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for early/intermediate stages; escalated BEACOPP for advanced-stage high-risk disease; brentuximab vedotin (BV) + AVD replacing bleomycin in high-risk advanced HL based on ECHELON-1 data. PET-adapted response evaluation guides escalation or de-escalation.
• Non-Hodgkin Lymphoma (Aggressive — DLBCL): R-CHOP (rituximab + CHOP) remains standard; polatuzumab vedotin-R-CHP (Pola-R-CHP) for high-IPI DLBCL based on POLARIX trial. Relapsed/refractory: R-ICE or R-DHAP salvage → autologous HSCT if chemosensitive; CAR-T (axicabtagene, tisagenlecleucel, lisocabtagene) for third-line and beyond.
• Follicular Lymphoma (Indolent NHL): Rituximab monotherapy or BR (bendamustine + rituximab); obinutuzumab-based combinations; lenalidomide + rituximab (R²); PI3K inhibitors (copanlisib, umbralisib) for relapsed disease.
• Multiple Myeloma: Frontline triplet VRd (bortezomib + lenalidomide + dexamethasone) or DRd (daratumumab + lenalidomide + dexamethasone) per MAIA trial; transplant-eligible patients proceed to autologous HSCT after 4–6 cycles of induction. Novel quadruplet induction (Dara-VRd) is now standard at high-volume centers. Relapsed myeloma: carfilzomib-based triplets, pomalidomide combinations, elotuzumab, isatuximab, selinexor, belantamab mafodotin, or teclistamab (BCMA-CD3 bispecific).
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Autologous HSCT: Patient's own stem cells collected post-induction and reinfused after high-dose conditioning (BEAM: carmustine, etoposide, cytarabine, melphalan for lymphoma; high-dose melphalan for myeloma). Hospital stay: 3–5 weeks. Engraftment typically by day +14–21.
Allogeneic HSCT: HLA-matched sibling or unrelated donor (MUD) or haploidentical (parent/child) transplantation. Myeloablative conditioning (MAC): TBI + cyclophosphamide or busulfan/cyclophosphamide. Reduced-intensity conditioning (RIC): fludarabine-based, for older or comorbid patients. Graft-versus-host disease (GvHD) prophylaxis: calcineurin inhibitors (tacrolimus/cyclosporine) + methotrexate or post-transplant cyclophosphamide (PT-Cy) for haplo-HSCT. Engraftment monitoring by chimerism studies (STR-PCR). Hospital stay: 4–8 weeks minimum inpatient; close outpatient follow-up for 3–6 months mandatory before international travel.
CAR-T CELL THERAPY (ADVANCED CELLULAR IMMUNOTHERAPY)
Chimeric Antigen Receptor T-cell (CAR-T) therapy is available at select JCI-accredited centers in India (Tata Medical Center Kolkata, AIIMS Delhi, Apollo Proton Cancer Centre Chennai) and leading UAE centers (Cleveland Clinic Abu Dhabi). Patient's T cells are collected via leukapheresis, genetically engineered to express CD19- or BCMA-targeted CARs, expanded ex vivo (3–4 weeks manufacturing), then reinfused after lymphodepleting chemotherapy (fludarabine/cyclophosphamide). Key toxicities — cytokine release syndrome (CRS, graded 1–4, managed with tocilizumab) and immune effector cell-associated neurotoxicity syndrome (ICANS) — require ICU-capable monitoring centers. Response rates in relapsed/refractory DLBCL: 40–58% complete remission.
TARGETED THERAPY & IMMUNOTHERAPY
BTK inhibitors: Ibrutinib, acalabrutinib, zanubrutinib — for CLL, MCL, Waldenström macroglobulinemia.
BCL-2 inhibitor: Venetoclax — CLL (with obinutuzumab), AML (with azacitidine, frontline in transplant-ineligible patients per VIALE-A trial).
Hypomethylating agents: Azacitidine, decitabine — MDS and AML maintenance post-transplant.
Checkpoint inhibitors: Pembrolizumab, nivolumab — relapsed/refractory Hodgkin lymphoma (anti-PD-1), and select NHL contexts.
Antibody-drug conjugates: Brentuximab vedotin (CD30), polatuzumab vedotin (CD79b), inotuzumab ozogamicin (CD22).
RADIATION THERAPY (ADJUNCT ROLE)
Consolidative involved-site radiation therapy (ISRT) using IMRT or VMAT for early-stage Hodgkin lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), or localized NHL; palliative RT for bone pain in myeloma; total body irradiation (TBI) as part of myeloablative HSCT conditioning at transplant-capable centers equipped with linear accelerators.
Cost of Blood Cancer Treatment: India vs. UAE
The cost of blood cancer treatment varies substantially depending on the diagnosis (leukemia, lymphoma, or myeloma), treatment modality (chemotherapy, targeted therapy, autologous or allogeneic stem cell transplant, or CAR-T cell therapy), number of cycles, and the level of institutional infrastructure required. India offers the same WHO-approved drug protocols, internationally validated diagnostic platforms (NGS, flow cytometry, PET-CT), and JCI- or NABH-accredited transplant units at 40–60% lower cost than equivalent UAE facilities, making it the preferred destination for complex, multi-cycle treatment courses. The UAE — particularly Cleveland Clinic Abu Dhabi, Mediclinic, and American Hospital Dubai — offers equivalent oncology standards with premium infrastructure, multilingual care teams, and significantly more accessible entry for GCC-region patients. GAF Healthcare provides transparent, itemized cost estimates inclusive of all hospital, pharmacy, and diagnostic charges before treatment commitment.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $7,000 – $55,000 | ~55% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $18,000 – $120,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (WEEKS 1–2)
• GAF Healthcare case coordinator collects all existing pathology, biopsy, and molecular reports and submits to the designated hematologist-oncologist in India or UAE for remote multidisciplinary tumor board (MDT) review.
• Second-opinion report, proposed treatment protocol, and itemized cost estimate issued within 5–7 business days.
• Medical visa (India: e-Medical Visa, single or multiple entry) or UAE entry visa facilitated by GAF Healthcare; standard processing 3–5 business days.
• Travel itinerary, airport pickup, and pre-selected hospital-proximate accommodation arranged for patient and one attendant.
PHASE 2 — ARRIVAL & DIAGNOSTIC CONFIRMATION (DAYS 1–5)
• Airport reception by GAF Healthcare ground team with dedicated language interpreter.
• Comprehensive baseline workup: CBC, bone marrow biopsy re-review (if slides available) or fresh biopsy, repeat PET-CT staging, ECHO, HLA typing (if HSCT track), NGS molecular panel, full metabolic panel.
• Formal MDT case conference: hematologist, medical oncologist, transplant specialist, radiation oncologist, infectious disease consultant, and clinical pharmacist confirm or adjust treatment protocol.
• Patient and family counseling session (with interpreter): treatment plan, expected timeline, toxicity risk profile, consent documentation.
PHASE 3 — TREATMENT INITIATION (DAYS 5–14 ONWARD)
• CHEMOTHERAPY TRACK: Induction chemotherapy commenced in a negative-pressure isolation room with HEPA filtration (standard at JCI-accredited centers). Continuous monitoring of CBC, electrolytes, LFTs, renal function. Tumor lysis syndrome (TLS) prophylaxis with allopurinol/rasburicase, aggressive IV hydration, and urine alkalinization protocols per institutional SOPs. Febrile neutropenia episodes managed per IDSA guidelines with broad-spectrum IV antibiotics and antifungal prophylaxis (fluconazole/posaconazole).
• TARGETED THERAPY/ORAL TKI TRACK (CML, CLL): Outpatient or short-stay initiation with pharmacokinetic counseling; adherence monitoring and drug interaction review performed by clinical pharmacist.
• INPATIENT STAY: Typically 14–28 days for a single induction cycle; response assessment by bone marrow aspirate/biopsy and PET-CT at end of cycle 2–3.
PHASE 4 — STEM CELL TRANSPLANT (IF APPLICABLE, WEEKS 4–12)
• AUTOLOGOUS HSCT: Stem cell mobilization with G-CSF ± plerixafor, apheresis collection, cryopreservation. High-dose conditioning (3–5 days). Stem cell reinfusion (Day 0). Engraftment monitoring (ANC >500 for 3 consecutive days, typically Day +10 to +14). Total hospital stay: 25–35 days post-conditioning.
• ALLOGENEIC HSCT: Donor workup (sibling or MUD) coordinated simultaneously. Conditioning regimen (7–10 days). Transplant day (Day 0). Close inpatient monitoring through Day +30; outpatient follow-up through Day +100. GvHD surveillance: skin, gut, liver. Chimerism and MRD assessments at Day +30, +60, +100.
• FIT-TO-FLY CLEARANCE: Allogeneic HSCT patients must complete a minimum of 90 days post-transplant with stable engraftment, no active GvHD above Grade 1, no active infection, and adequate performance status before international air travel is cleared by the transplant physician.
PHASE 5 — RESPONSE ASSESSMENT & CONSOLIDATION (WEEKS 6–16)
• End-of-induction PET-CT/bone marrow assessment to evaluate complete metabolic response (CMR), partial response (PR), or primary refractory disease (guides salvage decision).
• Consolidation cycles (if applicable): 2–4 additional chemotherapy cycles or maintenance TKI/lenalidomide.
• Discharge planning: GAF Healthcare coordinator provides a comprehensive discharge summary, all pathology, imaging, and molecular reports (digital and hard copy), and a detailed home oncologist handover letter with the treatment protocol, response data, and next monitoring schedule.
• Remote follow-up: Telemedicine consultations with the treating hematologist available at 30, 60, and 90 days post-discharge via GAF Healthcare's patient portal.
RECOVERY MILESTONES:
• Day +14 to +21 (chemotherapy): Bone marrow recovery, resolution of grade 3–4 neutropenia, safe for discharge if no active infection.
• Day +30 (autologous HSCT): Engraftment confirmed, outpatient status achieved.
• Week 6–8: End-of-induction response assessment completed; consolidation plan finalized.
• Week 10–16: Fit-to-fly assessment for most chemotherapy and autologous HSCT patients; allogeneic HSCT patients require 12–20 weeks minimum in-country.
Risks & Considerations
Blood cancer treatment carries substantial, protocol-specific risks that must be thoroughly understood before initiating therapy. Induction chemotherapy for AML or ALL induces prolonged profound pancytopenia (absolute neutrophil count <100/μL for 2–4 weeks), creating a critical window for life-threatening infections — bacteremia, invasive fungal infections (Aspergillus, Candida), and viral reactivation (CMV, EBV, VZV). Tumor lysis syndrome (TLS) — characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and acute renal failure — can occur within 12–72 hours of cytotoxic therapy initiation and requires ICU-level prophylactic and reactive management. Anthracycline-based regimens (daunorubicin, doxorubicin) carry cumulative cardiotoxicity risk, measured by serial ECHO assessment of LVEF; patients with pre-existing cardiac dysfunction require dose modification or liposomal formulation substitution. Allogeneic HSCT carries a transplant-related mortality (TRM) of 5–20% depending on donor type (matched sibling lowest, haploidentical highest), conditioning intensity, and patient comorbidity score (HCT-CI — Hematopoietic Cell Transplantation-specific Comorbidity Index). Graft-versus-host disease (GvHD) — both acute (skin, gut, liver, Grades I–IV) and chronic (multiorgan, NIH criteria) — is the primary cause of non-relapse morbidity after allogeneic HSCT; Grade III–IV acute GvHD carries a mortality rate of 30–50%. CAR-T cell therapy is associated with cytokine release syndrome (CRS) in 70–90% of patients (Grades 3–4 in 10–20%) and immune effector cell-associated neurotoxicity syndrome (ICANS, up to 60% of recipients), both requiring expert ICU management and access to tocilizumab and corticosteroids. TKI therapy (imatinib, dasatinib) is generally well tolerated but requires monitoring for pleural effusion (dasatinib-specific), QTc prolongation (nilotinib), and arterial occlusive events. All patients on immunosuppressive regimens require antiviral prophylaxis (acyclovir/valacyclovir), antifungal prophylaxis (fluconazole or posaconazole), and Pneumocystis jirovecii pneumonia (PJP) prophylaxis (trimethoprim-sulfamethoxazole or inhaled pentamidine). International patients must be counseled that treatment timelines are not fixed — disease response, toxicity management, and transplant recovery may extend the in-country stay beyond initial estimates, and flexibility in travel planning is essential.
Top Hospitals for Blood Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Blood Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vishnu Hari
DM, MD, MBBS
Medical Oncologist & Haematologist
Sarvodaya Hospital, Faridabad, India
16+ Yearsof experience
Dr. Vishnu Hari is an Associate Director and Head of Unit I in Medical Oncology, Haematology, and Bone Marrow Transplantation at Sarvodaya Hospital in Faridabad. With more than 16 years of clinical experience, he brings deep expertise in diagnosing and treating a broad spectrum of solid and haematological malignancies. His comprehensive training at the Regional Cancer Centre, Trivandrum, combined with his qualifications in internal medicine and general… Read more
Dr. Amita Mahajan
MBBS, MD (Pediatrics), MRCPCH, CCST (Advanced Training in Pediatric Oncology)
Pediatric Hematologist and Oncologist
Indraprastha Apollo Hospital, New Delhi, India
32+ Yearsof experience
Dr. Amita Mahajan is a Senior Consultant in Pediatric Hematology and Oncology at Indraprastha Apollo Hospital, New Delhi, with over 32 years of dedicated clinical experience in childhood blood disorders and cancers. She completed her MBBS and MD in Pediatrics from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by advanced international training: the MRCPCH from the Royal College of Paediatrics and Child Health, London, and… Read more
Dr. Govind Eriat
MBBS, DNB, FRCP, Fellowship in Leukemia/BMT
Hematologist & Hemato-Oncologist
Gleneagles Hospitals, Bengaluru, India
14+ Yearsof experience
Dr. Govind Eriat is a Visiting Consultant in Hematology and Hemato-Oncology at Gleneagles Hospitals, Bengaluru, bringing over 14 years of specialized clinical experience in blood disorders and cancer care. He holds an MBBS degree and has completed his DNB in Internal Medicine, establishing a strong foundation in comprehensive patient care. His international credentials include Fellowship from the Royal College of Physicians (FRCP), United Kingdom, and a… Read more
Dr. Parinitha Reddy Gutha
MBBS, MRCPCH, FRCPCH, CCT
Paediatric Oncologist & Haematologist
Yashoda Hospitals, Hyderabad, India
26+ Yearsof experience
Dr. Parinitha Reddy Gutha is the Clinical Director and Head of Department of Paediatric Oncology & Haematology at Yashoda Hospitals in Hyderabad. She holds the prestigious FRCPCH qualification from the Royal College of Paediatrics and Child Health, London, and brings over 26 years of comprehensive clinical expertise in diagnosing and treating childhood cancers, blood disorders, and performing paediatric bone marrow transplantation. Her training spans… Read more
Dr. Sanjeev Kumar Sharma
MBBS, MD (Medicine), DM (Clinical Hematology)
Hematologic Oncologist & Bone Marrow Transplant Specialist
BLK-Max Super Speciality Hospital, New Delhi, India
20+ Yearsof experience
Dr. Sanjeev Kumar Sharma is the Director of Haemato-oncology and Bone Marrow Transplant at BLK-Max Super Speciality Hospital in New Delhi, one of India's leading tertiary-care centers. With over 20 years of clinical experience, he is widely recognized for his expertise in hematologic malignancies and complex bone marrow disorders. His career has been built on a foundation of rigorous training in clinical hematology and a deep commitment to evidence-based… Read more
Frequently Asked Questions — Blood Cancer Treatment
The cost of blood cancer treatment varies significantly based on the type of cancer (leukemia, lymphoma, or multiple myeloma), the treatment protocol required, and whether hematopoietic stem cell transplantation (HSCT) or CAR-T cell therapy is involved. In India, at JCI- or NABH-accredited cancer centers, the total cost for a comprehensive treatment course — including chemotherapy induction cycles, diagnostics (NGS, PET-CT, bone marrow studies), and autologous or allogeneic stem cell transplantation — typically ranges from USD 7,000 to USD 55,000. A single chemotherapy induction course (e.g., 7+3 for AML or R-CHOP for DLBCL) ranges from USD 7,000–15,000, while allogeneic HSCT from a matched unrelated donor (MUD) ranges from USD 30,000–55,000. In the UAE, at JCI-accredited and DHA-licensed oncology centers in Dubai and Abu Dhabi, equivalent treatment costs range from USD 18,000 to USD 120,000, with allogeneic HSCT in the range of USD 70,000–120,000. India is typically 40–60% less expensive than the UAE for equivalent oncology protocols using the same WHO-approved drug regimens and international-standard diagnostics. GAF Healthcare provides fully transparent, itemized cost estimates inclusive of hospital stay, chemotherapy drugs, supportive medications, and monitoring investigations before any commitment is made.
The required in-country stay before international air travel is medically safe is highly dependent on the treatment modality. For patients receiving outpatient or short-stay chemotherapy cycles (e.g., CML patients on oral TKI therapy, or patients completing a single R-CHOP cycle for lymphoma), a minimum in-country stay of 3–4 weeks per cycle is recommended to allow for CBC recovery assessment, response evaluation, and management of any immediate toxicity. For patients undergoing autologous HSCT (common for multiple myeloma and relapsed Hodgkin/NHL), the minimum safe in-country stay is 6–8 weeks from the date of stem cell reinfusion (Day 0), once ANC engraftment is confirmed, no active infections are present, and the patient can independently manage oral medications. For patients undergoing allogeneic HSCT (matched sibling, MUD, or haploidentical donor transplant), international air travel is not medically cleared until a minimum of 90 days post-transplant, as this window is critical for GvHD surveillance, chimerism monitoring, immune reconstitution assessment, and infectious complication management. Patients who develop acute GvHD, viral reactivation (CMV, EBV), or delayed engraftment may require an extended stay of 4–5 months. GAF Healthcare works closely with the transplant physician team to provide patients with a formal fit-to-fly certificate, coordinate extended visa arrangements as needed, and arrange continuity of care documentation for the patient's home oncologist.
Success rates in blood cancer treatment vary considerably by diagnosis, disease stage, patient age, and molecular risk stratification, and the figures reported at JCI-accredited centers in India and the UAE are consistent with international benchmarks published by the NMDP, EBMT, and SEER. For Acute Lymphoblastic Leukemia (ALL) in children, complete remission rates exceed 95% with modern multi-agent protocols (BFM or COG-based), with 5-year event-free survival of approximately 85–90%. For adult ALL, 5-year overall survival ranges from 40–60%, improving significantly in BCR-ABL1-positive ALL with the addition of TKI therapy and CAR-T in the relapsed setting. For Acute Myeloid Leukemia (AML), induction remission is achieved in 60–80% of younger patients; 5-year overall survival with allogeneic HSCT in favorable-risk AML approaches 60–70%. For Diffuse Large B-Cell Lymphoma (DLBCL), first-line R-CHOP produces a 5-year overall survival of approximately 60–70%; patients achieving complete metabolic response (PET-negative) at end-of-treatment have outcomes exceeding 75%. For Hodgkin Lymphoma (early-stage), cure rates with ABVD or BV-AVD exceed 85–90%. For Multiple Myeloma, while not considered curable with current standard therapy, modern quadruplet induction followed by autologous HSCT and lenalidomide maintenance achieves a median progression-free survival of 5–7 years in transplant-eligible patients, with some patients achieving 10+ year remissions. For CML, treatment with second-generation TKIs achieves major molecular response (MMR) in over 80% of patients at 12 months, with near-normal life expectancy in optimal responders. GAF Healthcare facilitates treatment at high-volume centers where these outcomes are consistently achieved and where multidisciplinary tumor boards, molecular diagnostics, and advanced cellular therapy capabilities are all available under one roof.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international blood cancer patients traveling to India or the UAE, recognizing that oncology patients require a higher standard of logistical support than routine medical tourists.
INDIA — MEDICAL VISA & ENTRY: GAF Healthcare prepares and submits the Indian e-Medical Visa (and e-Medical Attendant Visa for one accompanying family member) application on behalf of the patient, including the official hospital invitation letter, diagnosis summary, and treatment confirmation required by Indian immigration authorities. The e-Medical Visa is typically approved within 3–5 business days and permits a stay of up to 60 days per entry, with up to 3 entries permitted. For patients requiring stem cell transplants (expected in-country stay of 3–5 months), GAF Healthcare coordinates medical visa extension through the Foreigners Regional Registration Office (FRRO) in the city of treatment with the treating hospital's support documentation.
UAE — ENTRY & VISA: Patients from over 120 nationalities receive visa-on-arrival or visa-free entry to the UAE for a minimum of 30 days, renewable. GAF Healthcare assists patients from nationalities requiring advance UAE entry visa with application preparation and DHA-facilitated medical treatment documentation. For extended treatment stays, tourist visa extensions and treatment-linked long-stay permits are coordinated through GAF Healthcare's UAE operations team.
AIRPORT TRANSFERS & GROUND LOGISTICS: Dedicated GAF Healthcare patient coordinators receive patients and attendants at the airport (Indira Gandhi International Delhi, CSIA Mumbai, RGIA Hyderabad, Abu Dhabi International, or DXB Dubai) and arrange private, accessible vehicle transport directly to the hospital or accommodation. Wheelchair assistance, porter support, and coordination with hospital admissions are pre-arranged.
DEDICATED INTERPRETERS & CULTURAL LIAISONS: For patients from Arabic, Russian, French, Swahili, or other language backgrounds, GAF Healthcare assigns a dedicated bilingual case coordinator who accompanies the patient to all clinical appointments, MDT discussions, and consent procedures. Written reports and discharge summaries can be prepared with certified translation.
ATTENDANT ACCOMMODATION: For long-duration blood cancer treatments (particularly HSCT), GAF Healthcare arranges fully furnished service apartments or hotel accommodation proximate to the treating hospital, negotiated at partner rates for the patient's attendant. Meal arrangements, local SIM cards, and 24/7 emergency helpline access are included in the GAF Healthcare coordination package. For patients who require attendant accommodation within the hospital itself, private room configurations accommodating one family caregiver are pre-requested during hospital booking.
TELEMEDICINE & FOLLOW-UP COORDINATION: Post-discharge, GAF Healthcare's patient portal facilitates secure video consultations between the patient (now at home) and the treating hematologist at 30, 60, and 90 days. All investigation requests (CBC, PCR monitoring for CML/ALL, MRD testing) are coordinated through GAF Healthcare's network of partner diagnostic labs in the patient's home country where available.
Patients Also Explore
Other treatments commonly sought by patients considering Blood Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology